Skip to main content

Alzheimer's Disease

Volume 448: debated on Monday 3 July 2006

To ask the Secretary of State for Health what answers her Department has received from the National Institute for Health and Clinical Excellence (NICE) to each of the six questions asked by her Department on 13 February 2006, Gateway reference 6185, in relation to the NICE appraisal of Donepezil, Rivastigmine, Galantamine and Memantine for the treatment of Alzheimer's disease. (81674)

The National Institute for Health and Clinical Excellence's responses to comments received on its appraisal of these drugs have been published on NICE'S website at www.nice.org.uk.